Archive photo: Laboratory, not identified as a Palvella facility. Polina Tankilevitch/Pexels (cropped)
Palvella Therapeutics said Wednesday that the FDA accepted its application for QTORIN rapamycin and granted Priority Review, setting a February 28, 2027 target action date for the proposed treatment of microcystic lymphatic malformations.
The filing acceptance and review designation are not approval. QTORIN rapamycin remains investigational and has not been approved by the FDA or any other regulator for any indication, the company said in its announcement.
The application covers a 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations, a rare condition involving malformed lymphatic vessels. Palvella describes the disease as lifelong and associated with persistent leaking, bleeding, recurrent infections and functional impairment.
Company cites Phase 3 evidence
Palvella said its submission includes the Phase 3 SELVA study, Phase 2 clinical results, published literature and other evidence concerning off-label rapamycin use. The company reported that SELVA achieved statistical significance across all six prespecified efficacy endpoints, with p-values below 0.001.
According to Palvella, 95% of participants aged six and older who completed the efficacy evaluation period improved on the study’s primary investigator-assessed endpoint. That percentage describes the specified completer group; it should not be read as an outcome for every enrolled patient.
The company reported no drug-related serious adverse events in SELVA and said systemic rapamycin concentrations remained below 2 nanograms per milliliter at every measured timepoint for all participants. These are the issuer’s descriptions of its evidence, not an independent FDA assessment published with the announcement.
Potential launch depends on approval
Palvella said it is preparing for a possible standalone U.S. launch in the first half of 2027, subject to FDA approval. Its preparations include medical affairs, patient services, specialist engagement and market-access planning.
The company says the candidate has also received Breakthrough Therapy, Fast Track and Orphan Drug designations. None of those designations, nor Priority Review or the target action date, establishes that the application will be approved.
JBizNews Desk | Wayne, Pennsylvania
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
